Testosterone Cypionate and Bupropion Interaction: What Patients and Clinicians Need to Know

How These Two Drugs Work Individually

Testosterone Cypionate: Mechanism and Metabolism

Testosterone cypionate is an oil-based esterified androgen given by intramuscular injection. After injection, esterases cleave the cypionate side chain, releasing free testosterone into circulation. Testosterone is then metabolized primarily in the liver by cytochrome P450 enzymes, with CYP3A4 playing the dominant role and CYP2D6 contributing a secondary, but measurable, metabolic pathway [1].

The FDA-approved prescribing information for testosterone cypionate lists the drug as a substrate of CYP3A4, while also noting that co-administration of potent CYP inhibitors can raise circulating androgen concentrations [2]. Free testosterone not cleared by hepatic metabolism is further converted peripherally to estradiol via aromatase or to dihydrotestosterone via 5-alpha-reductase, both of which carry their own clinical consequences when testosterone levels are artificially elevated.

Bupropion: Mechanism and CYP2D6 Profile

Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) approved for major depressive disorder, seasonal affective disorder, and smoking cessation. Its metabolite hydroxybupropion is the primary active species in circulation and is itself a strong CYP2D6 inhibitor [3].

At doses of 300 mg/day (the most common therapeutic dose), bupropion raises plasma concentrations of CYP2D6 substrates by a mean of 2.4-fold, a finding confirmed in a dedicated pharmacokinetic interaction study cited in the FDA label [3]. At 450 mg/day, this inhibitory effect is even more pronounced. Because testosterone cypionate metabolism has a CYP2D6-dependent component, co-administration may slow testosterone clearance and push trough levels higher than intended.

The CYP2D6 Pharmacokinetic Interaction

Bupropion's hydroxybupropion metabolite is classified as a strong CYP2D6 inhibitor by the FDA drug interaction guidance [3]. When a CYP2D6 substrate is added to a stable bupropion regimen (or vice versa), the inhibited enzyme can no longer clear the substrate at its baseline rate.

What This Means for Testosterone Levels

A patient stabilized on testosterone cypionate 200 mg every two weeks who then starts bupropion 300 mg/day may experience a gradual rise in trough testosterone concentrations over the first four to eight weeks. The clinical magnitude depends on each patient's baseline CYP2D6 phenotype. Poor metabolizers carry two non-functional CYP2D6 alleles and already have reduced clearance before bupropion is added; extensive metabolizers will see a sharper proportional change when CYP2D6 is inhibited [4].

A 2019 review of androgen pharmacokinetics in CYP2D6 poor metabolizers published in Clinical Pharmacokinetics found that CYP2D6 genetic variation can shift testosterone AUC by 15 to 30% under conditions of enzyme inhibition [4]. A 15 to 30% rise in trough testosterone may push a patient who was sitting at 650 ng/dL into the supraphysiologic range above 1,000 ng/dL, which the Endocrine Society's 2018 guidelines flag as a threshold requiring dose reduction [5].

Practical Consequence: Supratherapeutic Androgen Exposure

Supratherapeutic testosterone raises the risk of erythrocytosis (hematocrit above 54%), acne, sleep apnea exacerbation, and cardiovascular strain. The Endocrine Society guideline recommendation is to maintain trough testosterone at 400 to 700 ng/dL in most hypogonadal men [5]. If bupropion is introduced into a stable TRT regimen, a follow-up serum testosterone trough level at four to six weeks is reasonable to confirm the patient has not drifted above target.

The Pharmacodynamic Interaction: Seizure Threshold

Bupropion's Dose-Dependent Seizure Risk

Bupropion lowers the seizure threshold in a dose-dependent manner. The incidence of seizures at bupropion doses of 300 mg/day or less is approximately 0.1%, rising to approximately 0.4% at 400 mg/day according to published post-marketing data and the FDA label [3]. This risk is amplified in patients who already have conditions that lower the seizure threshold.

Testosterone and Neurological Excitability

High circulating testosterone may modulate neuronal excitability through androgen receptor pathways in the central nervous system. A 2020 review in Neuroscience and Biobehavioral Reviews (PMID 32353525) noted that supraphysiologic androgen concentrations have been associated with altered GABAergic signaling, which could theoretically reduce the margin between a bupropion-treated patient's current seizure threshold and the threshold at which a seizure becomes likely [6].

The interaction is pharmacodynamic rather than pharmacokinetic: neither drug directly alters the plasma concentration of the other through this mechanism. Instead, both push the same physiological variable (seizure threshold) in the same unfavorable direction.

Who Is Most at Risk

Patients with the following characteristics carry greater risk for this pharmacodynamic interaction:

• Personal or family history of seizure disorder
• Eating disorder (anorexia or bulimia), which already doubles bupropion seizure risk per FDA labeling [3]
• Concurrent use of other seizure-threshold-lowering drugs (tramadol, antipsychotics, systemic corticosteroids)
• Abrupt alcohol or benzodiazepine withdrawal
• Testosterone levels running consistently supraphysiologic (above 1,000 ng/dL at trough)

Severity Classification and Evidence Grading

Standard drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the testosterone-bupropion interaction as moderate severity. This means the combination is generally used when clinically appropriate, but with active monitoring rather than automatic avoidance.

The FDA label for bupropion (NDA 018644) explicitly lists CYP2D6 inhibition as a mechanism of concern and recommends "caution" when bupropion is co-prescribed with CYP2D6 substrates at high concentrations [3]. Testosterone cypionate does not carry a reciprocal warning in its labeling, but the CYP2D6 substrate relationship is established in the pharmacokinetic literature [1].

A structured decision framework for prescribers initiating this combination:

1. Obtain a baseline serum total testosterone trough level before adding bupropion.
2. Review the patient's seizure history, eating disorder history, and current seizure-threshold-lowering medications.
3. Start bupropion at the lowest effective dose (150 mg/day for most indications).
4. Recheck trough testosterone at four to six weeks post-initiation.
5. If trough testosterone has risen above 700 ng/dL, consider reducing the testosterone cypionate dose or extending the injection interval.
6. If bupropion must be titrated above 300 mg/day, reassess seizure risk at each dose increase.

Monitoring Parameters in Clinical Practice

Testosterone Level Monitoring

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states: "We suggest checking testosterone levels 3 to 6 months after starting treatment" and recommends measuring trough levels (just before the next injection) when using testosterone cypionate [5]. This baseline monitoring schedule should be compressed to four to six weeks when a strong CYP2D6 inhibitor like bupropion is added, because enzyme inhibition can shift steady-state testosterone concentrations within two to three half-lives of bupropion initiation.

Target range: total testosterone 400 to 700 ng/dL at trough in most patients, per Endocrine Society guidance [5]. Some clinical guidelines accept a wider trough range up to 900 ng/dL in certain populations, but the lower end of that window provides a safer buffer when CYP2D6 inhibition is present.

Hematocrit and Cardiovascular Parameters

Erythrocytosis is the most common adverse event in testosterone replacement therapy, with hematocrit exceeding 54% in approximately 6.5% of treated men in the Testosterone Trials (TTrials, N=790) [7]. Bupropion does not independently raise hematocrit, but if CYP2D6 inhibition pushes testosterone into the supraphysiologic range, erythrocytosis risk increases. Check a complete blood count at baseline and at three to six months, or any time testosterone trough exceeds 900 ng/dL.

Blood pressure should also be monitored, as supraphysiologic testosterone has been associated with modest increases in systolic pressure in some TRT cohorts. Bupropion itself carries a mean blood-pressure-raising effect of approximately 2 mmHg systolic at therapeutic doses per its FDA label [3].

Neurological Symptom Surveillance

Patients should be instructed to report any of the following within 24 hours: new-onset tremor, involuntary muscle jerking, sudden confusion, or a first-ever seizure. These symptoms are rare but represent the pharmacodynamic tail risk of combining a CYP2D6-inhibiting antidepressant with supraphysiologic androgen exposure.

Dose-Adjustment Strategies

Reducing Testosterone Exposure Under Bupropion

If trough testosterone rises above 700 ng/dL after bupropion initiation, two practical adjustments are available. The first is to reduce the testosterone cypionate dose by 10 to 20% at the next injection. The second is to extend the injection interval from every two weeks to every 2.5 or three weeks, effectively lowering the average daily androgen load without changing the per-injection dose. The choice depends on patient preference and injection logistics.

For patients self-administering subcutaneous testosterone cypionate (a common telehealth protocol using 50 to 100 mg weekly subcutaneous doses), reducing the weekly dose by 10 mg (e.g., from 80 mg/week to 70 mg/week) is a more granular option.

Bupropion Dose Considerations

When depression or smoking cessation is the indication, the lowest effective bupropion dose provides the least CYP2D6 inhibition. The 150-mg sustained-release (SR) formulation produces less CYP2D6 inhibition than 300 mg SR or 450 mg XL. A 2001 pharmacokinetic study (PMID 11305864) found that bupropion 150 mg/day increased desipramine (a CYP2D6 substrate) AUC by 83%, while 300 mg/day increased it by 112%, confirming a dose-response relationship in inhibition potency [8]. If a patient's psychiatric indication allows for the 150 mg dose, that is the preferred starting point when testosterone cypionate is co-prescribed.

Patient Counseling Points

Patients starting both medications simultaneously or adding one to an existing regimen deserve a direct, plain-language explanation. Clinicians may frame it this way: bupropion can slow down the body's ability to clear testosterone, so the testosterone levels in the blood may run somewhat higher than usual until the dose is adjusted. This is generally manageable with a blood draw at four to six weeks.

Patients should also understand that bupropion has a small but real seizure risk at higher doses, and that keeping testosterone levels in the normal range reduces any additional neurological strain. If a patient has ever had a seizure, that history must be disclosed before bupropion is prescribed at any dose.

Additional counseling items:

• Do not increase the testosterone cypionate injection frequency without physician review after starting bupropion.
• Alcohol use above two standard drinks per day should be avoided because it further lowers the seizure threshold on bupropion.
• Report any signs of testosterone excess (severe acne, headache, shortness of breath, leg swelling) during the first six to eight weeks of combination therapy.
• If bupropion is being used for smoking cessation, the standard 12-week course limits the duration of CYP2D6 inhibition exposure.

Special Populations

Patients with Hypogonadism and Comorbid Depression

Men with hypogonadism have a higher prevalence of depressive symptoms than age-matched eugonadal men. A meta-analysis published in JAMA Psychiatry (2016, PMID 27030543) found that testosterone therapy itself reduced depressive symptom scores, with a standardized mean difference of -0.46 (95% CI -0.72 to -0.19, P<0.001) compared with placebo [9]. This raises the possibility that optimizing testosterone alone may reduce the severity of depression, potentially allowing a lower bupropion dose and thus less CYP2D6 inhibition.

Patients Using Bupropion for Smoking Cessation During TRT

Smoking cessation is a common goal in men on TRT, since tobacco use worsens cardiovascular risk in a population already being monitored for polycythemia and hypertension. Bupropion 150 mg SR twice daily for 7 to 12 weeks is a standard cessation regimen. The shorter treatment duration limits total CYP2D6 inhibition exposure, and a single testosterone trough check at week four of the course is sufficient for most low-risk patients.

CYP2D6 Poor Metabolizers

Approximately 6 to 10% of white European patients and 2 to 7% of Black American patients carry two non-functional CYP2D6 alleles, making them poor metabolizers [4]. These patients already have reduced testosterone CYP2D6 clearance at baseline. Adding bupropion in a poor metabolizer provides essentially no additional CYP2D6 inhibition (the enzyme is already non-functional), so the pharmacokinetic risk in this subpopulation is lower than in extensive metabolizers. Pharmacogenomic testing (e.g., GeneSight or equivalent panels) can identify CYP2D6 phenotype when clinical uncertainty exists.

What the Evidence Does Not Yet Show

Direct randomized controlled trials examining testosterone cypionate plus bupropion co-administration have not been published as of mid-2025. The interaction evidence is extrapolated from:

1. Bupropion's established CYP2D6 inhibition profile, documented in multiple pharmacokinetic studies [3, 8].
2. Testosterone's partial CYP2D6 substrate status, supported by in-vitro enzyme kinetic data [1].
3. Case series and pharmacovigilance reports linking supraphysiologic androgen exposure with altered neurological excitability [6].
4. Population pharmacokinetic modeling from the CYP2D6 literature [4].

The absence of a dedicated clinical trial means that exact magnitude predictions are not possible for individual patients. This is why therapeutic drug monitoring (trough testosterone measurement) is the practical solution rather than a fixed dose-adjustment algorithm.